(D-Arg1,D-Trp7·9,Leu11)-Substance P

SKU: orb3053981

Description

Spantide antagonizes both bombesin & substance P. It is also tachykinin receptor antagonist.

Key Properties

• CAS Number: 91224-37-2
• MW: 1497.82
• Purity: >98% (HPLC)
• Formula: C₇₅H₁₀₈N₂₀O₁₃
• Solubility: H2O : 100 mg/mL (66.77 mM; ultraphonic)

Bioactivity

• In Vivo:
  Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals. Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e. g. , IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β. Animal model: Female, 8-week-old C57BL/6 (B6) and BALB/c mice. Dosage: 36 μg/mouse. Administration: IP on days-1 and 0 (day of infection) and daily through 5 days pi (post infection). Result: At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice. Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only